Role of Helicobacter pylori in the triggering and evolution of hemorrhagic gastro-duodenal lesions

xlomafota13 shared this article with you from Inoreader Role of <em>Helicobacter pylori</em> in the triggering and evolution of hemorrhagic gastro-duodenal lesions Via Experimental and therapeutic medicine Exp Ther Med. 2021 Oct;22(4):1147. doi: 10.3892/etm.2021.10582. Epub 2021 Aug 9. ABSTRACT The majority of studies concerning Helicobacter pylori (H. pylori) are oriented towards the implication of infection with H. pylori in processes that end in the formation of neoplasia, without assessing the impact of the bacterium in triggering acute gastroduodenal hemorrhagic episodes. The present study includes 166 patients with upper digestive hemorrhage, admitted to the ATI Clinic, the Gastroenterology Clinic or to the Surgery II Clinic of the County Emergency Clinical Hospital in Craiova, Romania between 2017 and 2019. All patients were monitored for evolution and received treatment according to current guidelines, and hemorrhagic lesions were biopsied. In the study group, 56.8% of the patients with upper gastrointestinal bleeding (UGIB) were positive for H. pylori and 43.2% were negative. In patients less than 50 years of age, non-steroidal anti-inflammatory drug (NSAID) use and H. pylori infection had a cumulative effect in causing bleeding lesions, but in patients older than 50 years of age, the use of NSAIDs was replaced by therapies with oral antiplatelet or anticoagulant agents. The need for hemostasis surgery was more common in patients who exhibited H. pylori-positive UGIB compared to H. pylori-negative (16 vs. 9.7%). In patients with H. pylori-positive hemorrhagic lesions, gastric resection was frequently required to obtain hemostasis. Persistence of H. pylori infection in patients with a history of gastric resection (4.1%) still predisposes to a hemorrhagic or neoplastic complication. PMID:34504 592 | PMC:PMC8392874 | DOI:10.3892/etm.2021.10582 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.